Streetbeat News

Analyst Ratings

MRTX

Morgan Stanley analyst Michael Ulz has maintained an Equal-Weight rating on Mirati Therapeutics (NASDAQ:MRTX) and lowered the price target from $42 to $37.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 1:45 pm

CWEN

Oppenheimer analyst Noah Kaye maintains an Outperform rating on Clearway Energy (NYSE:CWEN) but has lowered the price target from $40 to $38.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 1:44 pm

BSY

Oppenheimer analyst Kristen Owen maintains an Outperform rating on Bentley Systems (NASDAQ:BSY) and raises the price target from $63 to $64.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 1:44 pm

BLZE

Oppenheimer analyst Ittai Kidron has reiterated an Outperform rating on Backblaze (NASDAQ:BLZE) and maintained a $7.5 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 1:39 pm

ARVN

Oppenheimer analyst Mark Breidenbach has reiterated his 'Outperform' rating on Arvinas (NASDAQ:ARVN), maintaining a price target of $95.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 1:39 pm

ALDX

Oppenheimer analyst Justin Kim has reiterated an Outperform rating on Aldeyra Therapeutics (NASDAQ:ALDX) and maintained a $14 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 1:38 pm

CDRE

Stephens & Co. analyst Daniel Imbro has reiterated an Overweight rating on Cadre Hldgs (NYSE:CDRE) and maintained a $29 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 1:37 pm

DAR

Stephens & Co. analyst Ben Bienvenu has reiterated an Equal-Weight rating on Darling Ingredients (NYSE:DAR) and maintained a $65 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 1:36 pm

MRVI

Morgan Stanley analyst Tejas Savant has maintained an Overweight rating on Maravai LifeSciences (NASDAQ:MRVI) but lowered the price target from $27 to $12.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 1:36 pm

INGR

Stephens & Co. analyst Ben Bienvenu has reiterated an Overweight rating on Ingredion (NYSE:INGR), maintaining a price target of $130.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 1:36 pm